New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:07 EDTACORAcorda Therapeutics reports FDA issues CRL for Plumiaz
Acorda Therapeutics announced that the FDA has issued a Complete Response Letter, or CRL, for the New Drug Application for Plumiaz Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. A CRL is a communication from the FDA that informs a company that their review of the NDA is complete and the application cannot be approved in its present form. The company is currently developing a response to address the items outlined in the letter.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
16:43 EDTACOROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:13 EDTACOROn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTACORAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
August 24, 2015
18:55 EDTACOROn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTACORJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
17:45 EDTACORAcorda Therapeutics up 31.2% after PTAB denies both IPRs of Ampyra patents
Subscribe for More Information
17:44 EDTACORAcorda Therapeutics announces PTAB denies both IPRs of Ampyra patents
Acorda Therapeutics announced that the United States Patent and Trademark Office, or USPTO, Patent Trials and Appeal Board. or PTAB, will not institute the inter partes review, or IPR, of U.S. Patent Nos. 8,663,685 and 8,007,826. The '685 and '826 patents are two of five Orange Book-listed patents that apply to Ampyra Extended Release Tablets, 10 mg, a novel treatment for multiple sclerosis developed by Acorda. Ampyra is a standard of care for improving walking in MS. The '685 and '826 patents are set to expire in 2025 and 2027, respectively.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use